Clinical trials · Pennsylvania
Esophageal Carcinoma clinical trials in Pennsylvania
We’re tracking 19 recruiting esophageal carcinoma studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07283939Recruiting
Testing a tool to adjust chemo doses and reduce treatment delays
This trial tests a computer algorithm called PAGODA that helps doctors adjust chemotherapy doses for people with gastrointestinal cancers. The goal is to prevent unplanned treatment delays while keeping the treatment effective.
Allentown, PennsylvaniaAges 18 years+ - NCT05775939Recruiting
PET/CT scan study to track heart damage from cancer radiation
This study uses a special scan (PET/CT) to look for early heart (cardiac) injury caused by radiation treatment for lung or esophageal cancer. If you may be at higher heart risk from your planned radiation dose, the scan may help researchers better measure that damage over time.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06872515Recruiting
Exercise before esophageal cancer surgery
This trial tests if doing supervised exercise before esophageal cancer surgery (called prehabilitation) helps people recover better. You would follow a personalized exercise plan for at least 2 weeks before your scheduled surgery.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Broomall, PennsylvaniaAges 18 years+ - NCT06644781RecruitingPhase 3
Study of Ifinatamab Deruxtecan for advanced esophageal cancer
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
Hershey, PennsylvaniaAges 18 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06780111RecruitingPhase 1/Phase 2
Combination therapy study for advanced esophageal cancer
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06535607RecruitingPhase 2
Study of volrustomig for advanced solid tumors
This trial tests a new drug called volrustomig, alone or with other cancer treatments, for people with advanced or metastatic solid tumors. It aims to see if the drug can help shrink or control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07405151RecruitingPhase 1/Phase 2
New drug for advanced esophageal cancer after other treatments
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
York, PennsylvaniaAges 18–80 - NCT07001592RecruitingPhase 1
Injection of a modified virus for advanced GI and peritoneal cancers
This trial tests a modified virus injected directly into tumors to treat metastatic gastrointestinal and peritoneal cancers. It aims to see if this approach can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18–69 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Horsham, PennsylvaniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Philadelphia, PennsylvaniaAges 18–130 - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Allentown, PennsylvaniaAges 40–75
Esophageal Carcinoma trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting esophageal carcinoma studies listed above.
- UPMC Hillman Cancer Center · 7 studies
- Cancer Care Associates of York · 2 studies
- Geisinger Medical Center · 2 studies
- Geisinger Medical Oncology-Lewisburg · 2 studies
- Geisinger Wyoming Valley/Henry Cancer Center · 2 studies
- Lehigh Valley Hospital - Muhlenberg · 2 studies
- Lehigh Valley Hospital-Cedar Crest · 2 studies
- Lehigh Valley Hospital-Hazleton · 2 studies
What taking part in a esophageal carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Esophageal Carcinoma trials in other states
Common questions
- Are there esophageal carcinoma clinical trials in Pennsylvania?
- Yes. We're currently tracking 19 recruiting esophageal carcinoma studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a esophageal carcinoma study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a esophageal carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New esophageal carcinoma studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.